Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan;108(1):11-20.
doi: 10.1179/2047773214Y.0000000126.

Global practices of meningococcal vaccine use and impact on invasive disease

Asad Ali, Rabab Zehra Jafri, Nancy Messonnier, Carol Tevi-Benissan, David Durrheim, Juhani Eskola, Florence Fermon, Keith P Klugman, Mary Ramsay, Samba Sow, Shao Zhujun, Zulfiqar Bhutta, Jon Abramson
Review

Global practices of meningococcal vaccine use and impact on invasive disease

Asad Ali et al. Pathog Glob Health. 2014 Jan.

Abstract

A number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated meningococcal vaccines have lead to control of serogroup C meningococcal disease in the UK, Canada, Australia, Spain, Belgium, Ireland, and Iceland. Serogroup B disease, predominant in New Zealand, has been dramatically decreased, partly due to the introduction of an outer membrane vesicle (OMV) vaccine. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. The highest incidence region of the meningitis belt initiated vaccination with the serogroup A conjugate vaccine in 2010 and catch-up vaccination is ongoing. Overall results of this vaccine introduction are encouraging especially in countries with a moderate to high level of endemic disease. Continued surveillance is required to monitor effectiveness in countries that recently implemented these programs.

Keywords: Epidemiology,; Global,; Immunity,; Immunization schedule,; Invasive meningococcal disease,; Meningitis; Meningococcemia,; Meningococcus,; Serogroup,; Vaccines,.

PubMed Disclaimer

References

    1. Epidemics of meningococcal disease. African meningitis belt. Wkly Epidemiol Rec 2001;76(37):282–8. - PubMed
    1. Broker M, Fantoni S. Meningococcal disease: a review on available vaccines and vaccines in development. Minerva Med. 2007;98(5):575–89. - PubMed
    1. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 1969;129(6):1385–95. - PMC - PubMed
    1. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969;129(6):1367–84. - PMC - PubMed
    1. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–70. Bull World Health Organ. 1971;45(3):279–82. - PMC - PubMed

MeSH terms

LinkOut - more resources